Aerie Pharmaceuticals Incの内部者の所有権
Aerie Pharmaceuticals Incの内部者の所有権は何ですか。
Aerie Pharmaceuticals Incの内部者の所有権は1.79%です。
内部者の所有権の定義は何ですか。
管理の所有権(Insider Ownership)は、発行済株式総数で除したインサイダー（5％超を所有する株主または取締役または役員) が所有する株式総数によって計算されます。
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
NASDAQのセクタHealth Careにおける内部者の所有権の企業と比べるAerie Pharmaceuticals Inc
Aerie Pharmaceuticals Incは何をしますか。
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Aerie Pharmaceuticals Incと類似の内部者の所有権
- Louisiana-Pacificの内部者の所有権は1.79%です。
- Amedisysの内部者の所有権は1.79%です。
- Virtu Incの内部者の所有権は1.79%です。
- Palo Alto Networksの内部者の所有権は1.79%です。
- Palo Alto Networksの内部者の所有権は1.79%です。
- Middlesex Water Coの内部者の所有権は1.79%です。
- Aerie Pharmaceuticals Incの内部者の所有権は1.79%です。
- Quicklogic Corpの内部者の所有権は1.80%です。
- Monro Incの内部者の所有権は1.80%です。
- Strykerの内部者の所有権は1.80%です。
- Emcorの内部者の所有権は1.80%です。
- Ironwood Pharmaceuticals Incの内部者の所有権は1.80%です。
- Stinger Resourcesの内部者の所有権は1.80%です。